Johnson & Johnson Reports Strong Q2 Earnings and Sales Growth
Johnson & Johnson reported second-quarter earnings that exceeded Wall Street estimates due to strong performance from its pharmaceutical unit, particularly drugs Tremfya and Darzalex. The company raised full-year sales and profit forecasts as growth in key drug segments offset declines in other areas.
Tickers: $JNJ